A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure

International Peace Maternity and Child Health Hospital36 enrolled

Overview

This project will clarify the safety and effectiveness of human amniotic epithelial cells transplantation for the treatment of primary ovarian failure (POF) patients and provide a new therapeutic method for patients with infertility.

POF is a defect characterized by the premature depletion of ovarian follicles. Patients with POF suffer from amenorrhea, infertility, low levels of estrogen, and high gonadotropin concentration before the age of 40. The early failure of ovarian function leads to lost fertility and increases risk of osteoporosis and cardiovascular disease, which has serious impact on the patient's physical, mental health and family stability. The etiology of POF is complex, and so far there has not been any effective treatment. Recent study showed that human amniotic epithelial cells (hAECs), also known as the birth waste, are newly discovered adult stem cells. The hAECs have the ability to repair nerve damage, myocardial injury, as well as liver damage. hAECs have low immunogenicity and no ethical restrictions. Therefore, hAECs are expected to become the new seed cells for regenerative medicine. Our previous study was the first to show that human amniotic epithelial cells have the ability to restore folliculogenesis in a mouse model with chemotherapy-induced premature ovarian failure. Our further studies demonstrated that hAECs either directly transdifferentiated into granulosa cells, or inhibited tumor necrosis factor-alpha-mediated granulosa cell apoptosis and reduced the inflammatory reaction in ovaries induced by chemotherapeutics, regulating VEGFA and its receptors to induce follicular growth related to paracrine activity. Therefore, it is necessary to start the clinical study of human amniotic epithelial cells transplantation in the POF disease which may offer a novel therapeutic strategy for improving the quality of life of POF patients.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Primary Ovarian Insufficiency Premature Ovarian Failure Infertility

Interventions

human amniotic epithelial cells (hAECs) transplantationBIOLOGICAL

hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 3×10\^7 hAECs in 4.5ml is separately injected into ovarian tissue by bilateral ovarian artery infusion.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. ≥18 and\<45 years old. 2. Female patients with documented diagnosis of POF: \<40 years old, at least 4 months of amenorrhea not due to pregnancy, two FSH levels above 40 IU/L, at least one month apart. 3. Not in other trial within 3 months prior to the start of this trial. 4. Willing to participate in this trial and to give informed consent/assent before any procedures are performed in this trial. Exclusion Criteria: 1. History of, or evidence of current malignancy within the past 5 years. 2. Severe functional impairment of vital organs. 3. Abnormal karyotype. 4. Coagulation disorders. 5. Severe pelvic adhesions. 6. Uncontrolled acute or chronic gynecologic inflammation. 7. Congenital adrenal cortical hyperplasia. 8. Cushing's syndrome. 9. Thyroid dysfunction. 10. Pituitary adenoma. 11. Pituitary amenorrhea or Hypothalamic amenorrhea. 12. Thrombophlebitis, venous thrombosis or artery thrombosis. 13. History of Oophorocystectomy. 14. Currently pregnant or breast-feeding. 15. Currently receiving other treatment that might affect the efficacy and safety of stem cells. 16. History of severe drug allergy. 17. Active infection detected by chest X-ray/CT. 18. HIV, TPAb positive. 19. Mental illness. 20. Currently participating in any other clinical trial that uses interventional drugs or examinations. 21. Patients that are deemed, by the investigator, inappropriate to participate in this trial.

Locations (1)

The International Peace Maternity and Child Health Hospital

Shanghai, Shanghai Municipality, China

Outcomes

Primary Outcomes

Safety and Tolerability assessed by Adverse Events

Proportion of patients with adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESI，such as acute allergic reaction, ectopic mass formation related to treatment)

Time frame: 150 days

Secondary Outcomes

Change from baseline in bilateral ovarian volume

The ovarian volume will be assessed by pelvic ultrasound on 30th, 90th, 150th days after transplantation.

Time frame: 150 days

Change from baseline in number of antral follicles (AFC)

The number of antral follicles developing will be assessed by pelvic ultrasound on 30th, 90th, 150th days after transplantation.

Time frame: 150 days

Change from baseline in Follicle-stimulating hormone (FSH) serum level

Serum FSH level will be tested on 30th and 150th days after transplantation.

Time frame: 150 days

Change from baseline in Luteinizing hormone (LH), Estradiol (E2), Testosterone (T), Prolactin (PRL) , Anti-müllerian hormone (AMH) serum level

Serum LH, E2, T, PRL, AMH level will be tested on 30th and 150th days after transplantation.

Time frame: 150 days

Menstruation resumption

Patients will monitor for resumption of menses within 150 days after transplantation. If the menstruation resumption rate is over 30%, the treatment will be considered effective.

Time frame: 150 days

Endometrial thickness

The endometrial thickness will be assessed by pelvic ultrasound on 30th, 90th, 150th days after transplantation.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.